Not yet a year old, Beijing-based start-up BeiGene Ltd. entered an agreement with Merck & Co. Inc., which will provide unspecified debt and equity financing to help support BeiGene's preclinical discovery, cancer biomarker research and clinical-stage oncology candidate development.